UNSPSC 51434107: Hexamethonium bromide

This classification denotes a nicotinic antagonist with the molecular formula C12H30N2.2Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8J77X3S603, chemically known as 1,6-hexanediaminium, n,n,n,n,n,n-hexamethyl-, dichloride but more generally known as hexamethonium bromide, which bears US NIH Compound Identifier 3604. European Medicines Agency schedules Hexamethonium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08028MIG.

UNSPSC 51434107 Hexamethonium bromide, a Commodity code, nominally names a specific pharmaceutical compound, but recent state and local opportunities show that purchasing under this code spans emergency medical medications and generic multi-source pharmaceuticals supplied to public health systems, fire rescue services, and pharmacy benefit programs. The buying bodies include municipal fire rescue departments (Tampa Fire Rescue), state health agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances representing multiple states and localities (Minnesota Multistate Cooperative Purchasing Alliance). Work is solicited as sealed competitive bids for firm-priced medication supplies with strict expiration and delivery requirements, ranging from narrow emergency-medication line items to broad multi-state generic pharmaceutical catalogs. Vendors must comply with FDA manufacturing standards, Drug Supply Chain Security Act requirements, and OSHA safety documentation; manage inventory replacement protocols; and in some cases maintain relationships with multiple authorized wholesalers and chargebacks systems.

Geographic activity centers on Texas, Florida, and Minnesota-led multi-state cooperative arrangements. The City of Tampa's Purchasing Department issued IFB 26P00188 on April 24, 2026, for Advanced Life Support Medications (response due April 8, 2026) with an estimated contract value of $40,000, soliciting Labetalol, Epinephrine, Adenosine, and Diltiazem; the contract includes a 5 percent small local business enterprise bid discount. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Department of Administration issued RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through MMCAP, with contract commencement July 1, 2026, requiring vendors to maintain inventory and compliance certifications and accept 3 percent administrative fees on all purchases. Recent activity reflects increasing state and local interest in direct manufacturing relationships, emergency medication stockpiling, and cooperative multi-state sourcing to manage pharmaceutical costs and supply chain resilience.